Singh et al. designed three immunotherapies, including CAR-T therapy, based on human anti-CD133 antibody fragments targeting unique epitopes present in glycosylated and non-glycosylated CD133, and investigated their targeting of CD133+ cells in a GBM humanized mouse model. This evidence concerns the gene PROM1 and glioblastoma.